縱橫股份(688070.SH):公司及子公司被美國列入實體清單,該事項對公司生產經營的影響總體可控
格隆匯5月10日丨縱橫股份(688070.SH)在投資者互動平台表示,公司關注到5月9日美國商務部將縱橫股份及子公司大鵬無人機列入實體清單事宜。作為國內全譜系工業無人機領軍企業之一,公司專注於無人機領域相關產品的研發、生產、銷售及服務,致力於為客户提供智能化、平台化、工具化的無人機系統。目前公司使用部分通用進口元器件應用於無人機系統,相關飛控與導航系統、任務載荷等核心產品已有國產化替代方案。本次公司及子公司被美國列入實體清單,該事項對公司生產經營的影響總體可控,當前公司各項業務有序推進,經營活動正常開展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.